Publication list
2022
Guti, E.,
Regdon, Z.,
Sturniolo, I.,
Kiss, A.,
Kovács, K.,
Demény, M.,
Szöőr, Á.,
Vereb, G.,
Szöllősi, J.,
Hegedűs, C.,
Polgár, Z.,
Virág, L.:
The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC.
Cancer Immunol. Immunother. 71 (9), 2151-2168, 2022.
Journal metrics:
Q1 Cancer Research
Q1 Immunology
Q1 Immunology and Allergy
D1 Medicine (miscellaneous)
Q1 Oncology
2021
Regdon, Z.,
Demény, M.,
Kovács, K.,
Hajnády, Z.,
Nagy-Pénzes, M.,
Bakondi, E.,
Kiss, A.,
Hegedűs, C.,
Virág, L.:
High-Content Screening identifies inhibitors of oxidative stress-induced parthanatos: cytoprotective and anti-inflammatory effects of ciclopirox.
Br. J. Pharmacol. 178 (5), 1095-1113, 2021.
Kiss, A.,
Csikos, C.,
Regdon, Z.,
Polgár, Z.,
Virág, L.,
Hegedűs, C.:
NMNAT1 Is a Survival Factor in Actinomycin D-Induced Osteosarcoma Cell Death.
Int. J. Mol. Sci. 22 (16), 1-17, 2021.
Journal metrics:
Q2 Catalysis
Q1 Computer Science Applications
Q1 Inorganic Chemistry
Q1 Medicine (miscellaneous)
Q2 Molecular Biology
Q1 Organic Chemistry
Q1 Physical and Theoretical Chemistry
D1 Spectroscopy
2020
Kiss, A.,
Ráduly, A.,
Regdon, Z.,
Polgár, Z.,
Tarapcsák, S.,
Sturniolo, I.,
El-Hamoly, T.,
Virág, L.,
Hegedűs, C.:
Targeting nuclear NAD+ synthesis inhibits DNA repair, impairs metabolic adaptation increases chemosensitivity of U-2OS osteosarcoma cells.
Cancers (Basel). 12 (5), 1-27, 2020.
Journal metrics:
Q2 Cancer Research
Q1 Oncology
updated: 2024-11-06, 14:21
